On 11 June 2019 the EU published Regulation (EU) 2019/933. This introduces a so-called “manufacturing waiver” by amending existing Regulation (EC) 469/2009 concerning supplementary protection certificates (SPCs).
The new Regulation is the result of a trilogue inter-institutional negotiation procedure between the European Commission, Council and Parliament, which concluded in February 2019 and is discussed here. The compromise text underwent a formal first reading at the European Parliament on 17 April 2019. It was approved by Council on 14 May 2019 and signed by the European Parliament and Council on 20 May 2019.
The Regulation was published in the EU Official Journal on 11 June 2019 (see here) and will enter into force on 1 July 2019.
The new Regulation amends the existing SPC Regulation to exclude certain acts from the protection conferred by SPCs.
In particular, a third party (referred to as a “maker”) is permitted to manufacture a medicinal product protected by an SPC for the exclusive purpose of export to countries outside the EU.
The rights of manufacture include authorisation for ancillary activities which are “strictly necessary” to enable the manufacture and export of the product. These include, for example, the importation of API into the EU to enable the preparation of a formulated medicinal product and the temporary storage of product or medicinal product within the EU for the exclusive purpose of export to countries outside the EU. Rights will also extend to contract manufacturing organisations and distributors acting on behalf of the party which is exporting the medicinal product.
In addition, for the final six months prior to SPC expiry, the right to manufacture extends to manufacture for stockpiling in the country of manufacture for release on to the market in the EU upon SPC expiry.
The Regulation imposes some formal requirements on any maker seeking to take advantage of the waiver. In particular:
These requirements are discussed further below.
The Regulation imposes an ongoing obligation to notify the national patent office and the SPC holder of specified information no later than three months before the start date of manufacture in the member state, or no later than three months before the first related act prior to that making, if earlier. The notice must specify:
Any changes in the above details must be notified to the national patent office and certificate holder before the changes take effect. The information together with the date of notification and any changes shall be published by the national patent office as soon as possible. Member states may impose a fee for the notification.
The maker does not need to provide information on the specific manufacturing location or on the timing of intended manufacture. Consequently, despite the fact that national patent offices can apply a fee to notifications, it is possible that “makers” with no concrete plans to manufacture will file precautionary notifications in case they want to manufacture in the future. As a result, it may be difficult for the SPC holder to identify which makers will in fact enter the market for export and/or stockpiling, and when.
The maker must ensure that the following logo is affixed to the outer packaging of the product or medicinal product. Where feasible, the logo should also be affixed to the immediate packaging.
The maker must ensure that any third party contracted to carry out “strictly necessary” related acts is fully informed and aware that those acts are subject to the conditions for application of the waiver (including the export only condition). The third party must be informed that placing on the market (other than by the maker in a notified non-EU export country), import or re-import of the product might infringe the SPC.
The new Regulation comes into force on 1 July 2019. The following transitional provisions apply.
In view of the above, it is advisable where possible to file new SPC applications prior to 1 July 2019.